Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.69 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.69 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640373 | 1.00 | SLC29A1 (0.74) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL20626401 | 1.00 | SLC29A1 (0.74) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL19583087 | 1.00 | SLC29A1 (0.74) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL17825976 | 1.00 | SLC29A1 (0.74) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL14713274 | 1.00 | SLC29A1 (0.74) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL20626400 | 1.00 | SLC29A1 (0.74) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL17825924 | 0.90 | ADORA3 (0.73) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL639839 | 0.90 | ADORA3 (0.73) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL19582953 | 0.90 | ADORA3 (0.73) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL639840 | 0.90 | ADORA3 (0.73) | SLC29A1ADORA3TP53TDP1PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102812033-B | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2015-11-25 | — | — | CN | claimed |
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2006-07-27 | — | — | US | claimed |
| EP-1575973-A2 | SUBSTITUTION DERIVATIVES OF N SP 6 SP -BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058791-A2 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2004-07-15 | — | — | WO | claimed |
| CN-102812033-A | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INST MATERIA MEDICA CAMS | 2012-12-05 | — | — | CN | disclosed |
| US-8119614-B2 | Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2012-02-21 | — | — | US | disclosed |
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2006-07-27 | — | — | US | disclosed |
| EP-1575973-A2 | SUBSTITUTION DERIVATIVES OF N SP 6 SP -BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058791-A2 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ADAR, ADORA2A, AMPD2 | SLC29A1 399/4885ADORA3 14/4885TP53 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.